证券代码：688221 证券简称：前沿生物 公告编号：2026-003 1、经财务部门初步测算，预计2025年度实现营业收入约14,000.00万元到 14,500.00万元，同比增加8.13%到11.99%，营业收入主要来自抗HIV创新药艾可 宁®（通用名：艾博韦泰）、代理产品缬康韦®（盐酸缬更昔洛韦）及报告期内获 批的远红外治疗贴（小沿易贴®）的销售收入。 前沿生物药业（南京）股份有限公司 2025 年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 2、经财务部门初步测算，预计2025年度归属于上市公司股东的净利润亏损 约25,500.00万元到亏损29,000.00万元，增加亏损约5,361.74万元到8,861.74 万元，主要系2024年度处置子公司股权产生7,183.65万元的投资收益，2025年度 无该类投资收益所致；预计2025年度归属于上市公司股东的扣除非经常性损益的 净利润亏损约28, ...

证券日报网讯1月26日，前沿生物在互动平台回答投资者提问时表示，FB7013作为全球首个申报临床、 靶向补体凝集素途径关键蛋白MASP-2的siRNA药物，具备同类首创(First-in-Class)潜力，临床前数据显 示，在健康食蟹猴中，单次皮下注射后血清MASP-2蛋白最大敲降幅度超95%，药效可持续105天以上， 预期临床阶段有望实现每3-6个月给药一针的便捷频率，可大幅提升患者用药依从性；在食蟹猴IgA肾病 模型中，该药物能剂量依赖性改善尿总蛋白肌酐比值(uPCR)、尿总蛋白(uTP)及肾小球滤过率(eGFR)等 核心指标，高剂量治疗8周后肾小球IgA沉积减少43%，系膜细胞数量下降36%，且脱靶分析显示无明显 脱靶风险，安全性良好。截至2025年末，公司已就FB7013向国家药监局提交IND申请并获受理， FB7013正式进入临床申请审批通道。关于BD合作事宜，公司始终秉持开放的态度，积极探索符合产品 发展战略的合作机会。 ...

1月23日，前沿生物涨5.07%，截至发稿，报27.34元/股，成交2.51亿元，换手率2.52%，总市值102.41亿 元。 资料显示，前沿生物药业(南京)股份有限公司位于江苏省南京市江宁区东山街道绿地之窗E-2栋11层， 成立日期2013年1月15日，上市日期2020年10月28日，公司主营业务涉及前沿生物是一家致力于研究、 开发、生产及销售针对未满足的重大临床需求的创新药的创新型生物医药企业。公司拥有一个已上市且 在全球主要市场获得专利的原创抗艾滋病新药,两个处于临床试验阶段、已获专利(或专利许可)的在研新 药。同时,公司拥有行业先进的长效多肽药物研发实力、经验丰富的研发团队、GMP认证的生产设施、 中国市场的医学推广团队和海外市场开拓团队,覆盖从创新药物发现、临床前研发和全球临床开发、生 产与销售的全产业链,在HIV长效治疗及免疫治疗细分领域具有较强竞争力。主营业务收入构成为：艾 可宁91.29%，其他8.71%。 从前沿生物十大流通股东角度 数据显示，易方达基金旗下1只基金位居前沿生物十大流通股东。易方达医疗保健行业混合A （110023）三季度新进十大流通股东，持有股数771.73万股，占流通股的 ...

证券代码：688221 证券简称：前沿生物 公告编号：2026-002 前沿生物药业（南京）股份有限公司 关于完成公司住所变更的工商登记并 换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 前沿生物药业（南京）股份有限公司（以下简称"公司"）于2025年10月29日召 开第四届董事会第八次会议审议《关于变更公司住所、取消监事会、修订<公司章程> 并办理工商变更登记的议案》，同日召开第四届监事会第八次会议审议《关于取消监 事会并废止公司部分治理制度的议案》，以上议案已经公司于2025年11月19日召开的 2025年第三次临时股东大会审议通过；同时股东大会授权公司管理层或其授权代表办 理相关事项的工商变更登记及备案手续。具体公告内容详见2025年10月31日公司披露 于上海证券交易所网站（http://www.sse.com.cn/）的《前沿生物关于变更公司住所、 取消监事会、修订<公司章程>暨修订、新增及废止公司部分治理制度的公告》 （2025-042）。 近期公司完成了以上事项的变更登记及备案，并收到了南 ...

证券之星消息，1月9日化学制药板块较上一交易日上涨1.77%，前沿生物领涨。当日上证指数报收于 4120.43，上涨0.92%。深证成指报收于14120.15，上涨1.15%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688221 | 前沿生物 | 28.15 | 19.99% | 30.53万 | | 7.86亿 | | 688091 | 上海谊众 | 60.84 | 17.29% | 11.94万 | | 6.88亿 | | 688658 | 悦康药业 | 31.79 | 17.13% | 20.04万 | | 5.86亿 | | 600513 | 联环药业 | 21.11 | 10.01% | 1 30.53万 | | 6.20亿 | | 601089 | 福元医药 | 30.27 | 9.99% | 10.86万 | | 3.10亿 | | 688356 | 键凯科技 | 101.00 | 8.57% | 3.59万 | | 3.51亿 ...

Core Viewpoint - The ChiNext 50 Index experienced a significant increase on January 9, closing at 1475.97 points with a rise of 1.43%, reflecting a strong market performance despite initial fluctuations [1]. Group 1: Market Performance - The ChiNext Composite Index rose by 2.08% to close at 1803.4 points, with a total trading volume of approximately 327.2 billion yuan [1]. - The average increase for the 600 stocks on the ChiNext board was 2.04%, with an average turnover rate of 4.48% and a total trading volume of 327.2 billion yuan [1]. - The index showed a volatility of 2.73% during the trading session, indicating active trading [1]. Group 2: Sector Performance - Communication equipment and chemical pharmaceutical stocks demonstrated strong performance, while semiconductor and healthcare stocks faced declines [1]. - Individual stock performances included Zhenyou Technology, Xinke Yidong, and Qianyan Biology reaching the daily limit up, while Shengbang Security saw a decline of 7.18%, marking the largest drop [1]. Group 3: Trading Details - Cambrian Technology led in trading volume with 14.9 billion yuan, while ST Yifei had the lowest trading volume at 1.259 million yuan [2]. - Strong Yi Co. had the highest turnover rate at 39.07%, while Longteng Optoelectronics recorded the lowest at 0.28% [2].

Core Viewpoint - The pharmaceutical sector is experiencing significant stock price increases, with notable gains in several companies, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Performance - Weikang Pharmaceutical has seen its stock price rise by over 15% [1]. - Frontline Bio and Shanghai Yizhong have both increased by over 10% [1]. - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical are also experiencing upward trends in their stock prices [1].

Core Viewpoint - The innovative drug sector experienced a significant rally, with notable stock price increases among various companies [1] Group 1: Company Performance - Weikang Pharmaceutical saw its stock price rise by over 18% [1] - Qianfang Bio and Shanghai Yizhong both increased by more than 10% [1] - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical also experienced upward movement in their stock prices [1]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks, with notable gains including a 20% limit up for Beibetter-U and over 17% increase for Yinos [1] - Other significant performers included Chengdu XianDao with over 13% rise, and Panlong Pharmaceutical with a 10% limit up [1] - Additional stocks such as Sunshine Nuohuo and Zhaoyan New Drug also experienced increases of over 9% and 7% respectively [1] Group 2 - The table lists various stocks with their respective price changes, total market capitalization, and year-to-date performance, highlighting Beibetter-U's market cap at 18.6 billion and a year-to-date increase of 42.46% [2] - Yinos has a market cap of 7.611 billion with a year-to-date increase of 22.29%, while Chengdu XianDao's market cap is 12.2 billion with a 29.59% increase [2] - Other notable stocks include Panlong Pharmaceutical with a market cap of 3.706 billion and a 13.07% year-to-date increase, and Sunshine Nuohuo with a market cap of 8.188 billion and a 17.63% increase [2]